Please login to the form below

Not currently logged in
Email:
Password:

Dr Christian Itin joins Cytos Biotechnology as CEO

He moves to the Swiss biotech from Micromet

Cytos Biotechnology CEO Dr Christian ItinSwiss biotech company Cytos Biotechnology has appointed Dr Christian Itin to be its new CEO.

He has also been elected to Cytos' board of directors and will be proposed as its new chairman, succeeding Dr Thomas Hecht, at an extraordinary shareholders meeting next month.

Dr Itin joins Cytos from Micromet, where he served as CEO for eight years until the biopharmaceutical company was acquired by Amgen earlier this year for $1.2bn.

In total he spent 13 years in senior management roles at Micromet, prior to which he co-founded US protein chip company Zyomyx.

Commenting on the appointment Dr Hecht said: “Christian is an experienced biotech leader with significant expertise and a proven track record and his appointment completes our restructuring of Cytos. We believe with his experience and skills that he is well positioned to shape Cytos' future.” 

Cytos' board will see a further change next month, when non-executive member, and its former chief financial officer Jakob Schlapbach will set down at the shareholder meeting.

18th October 2012

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics